No Prescription |
 |
 | ||
|
PARAXIN Chloromycetin |
|
| ||
No Prescription » Prescription Drugs 13 » PARAXIN Chloromycetin Chloramphenicol is primarily bacteriostatic. It binds to the 50S subunit of the ribosome thereby inhibiting bacterial protein synthesis.Chloramphenicol has a wide spectrum of activity against gram-positive and gram-negative cocci and bacilli (including anaerobes) Rickettsia Mycoplasma and Chlamydia and Chlamydophila. Because of bone marrow toxicity the availability of alternative antibiotics and the emergence of resistance chloramphenicol is no longer a drug of choice for any infection except serious infections due to a few multidrug-resistant pathogens that retain susceptibility to this antibiotic. However outcomes of chloramphenicol treatment of meningitis caused by relatively penicillin-resistant pneumococci have been discouraging. Buy PARAXIN Chloromycetin and other Prescription Drugs 13 products online at Medstore. 882
About PARAXIN Chloromycetin: Product Type: Prescription Drugs 13 PARAXIN ( Chloromycetin Generic Chloramphenicol ) PARAXIN (Chloromycetin Generic Chloramphenicol) Chloromycetin Generic Chloramphenicol 250mg Caps 10 Chloromycetin Generic Chloramphenicol PARAXIN
View more Prescription Drugs 13 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
